NovoCure
NVCR
Market cap $1.23B

10.97 USD

-0.41

3.60%

At close Jul 30, 4:00 PM EDT

After hours

11.41

+0.44

4.01%

1 day

-3.60%

5 days

-33.52%

1 month

-38.37%

3 months

-39.53%

6 months

-57.00%

Year to date

-63.42%

1 year

-53.02%

5 years

-85.60%

10 years

-39.99%

About: NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Employees: 1,488

Healthcare Medical Devices

0

Funds holding %

of 7,323 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

692% more call options, than puts

Call options by funds: $21.2M | Put options by funds: $2.68M

1.97% more ownership

Funds ownership: 84.63% [Q4 2024] → 86.6% (+1.97%) [Q1 2025]

7% less repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 76

5% less funds holding

Funds holding: 238 [Q4 2024] → 227 (-11) [Q1 2025]

17% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 47

38% less capital invested

Capital invested by funds: $2.73B [Q4 2024] → $1.7B (-$1.03B) [Q1 2025]

60% less funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 2 (-3) [Q1 2025]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$14.50

32%

upside

Avg. target

$26

139%

upside

High target

$34

210%

upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

Wells Fargo Larry Biegelsen	32%upside $14.50	Equal-Weight Downgraded	25 Jul 2025
Ladenburg Thalmann Kevin DeGeeter	173%upside $30	Buy Initiated	8 Jul 2025
Piper Sandler Jason Bednar	210%upside $34	Overweight Reiterated	27 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 11 articles about NVCR published over the past 30 days

NovoCure's Wearable Oncology Edge And Compelling Valuation

NVCR focuses on Tumor Treating Fields wearables for GBM, mesothelioma, and NSCLC. These are its main recurring revenue verticals. So far, its wearables have shown favorable safety profiles, and suggest they should be a net benefit across other oncology niches. NVCR's late‑stage PANOVA‑3 and METIS trials could continue growing their markets. Currently, management is targeting more PMA filings later this year.

NovoCure's Wearable Oncology Edge And Compelling Valuation

Top 3 Health Care Stocks That May Explode In July

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks That May Explode In July

NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript

NovoCure Limited (NASDAQ:NVCR ) Q2 2025 Earnings Conference Call July 25, 2025 8:00 AM ET Company Participants Ashley Cordova - CEO & Director Christoph Brackmann - Chief Financial Officer Frank Leonard - Executive VP & President of Novocure Oncology Ingrid Goldberg - VP of Investor Relations William F. Doyle - Executive Chairman Conference Call Participants Emily Claudia Bodnar - H.C.

NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript

The Motley Fool

NovoCure Q2 Revenue Jumps 6 Percent

NovoCure (NVCR -23.93%), the oncology device firm advancing Tumor Treating Fields therapy, released its second quarter 2025 results on July 24, 2025. GAAP revenue totaled $158.8 million in Q2 2025, an increase of 6% year over year and surpassing the $154.16 million analyst consensus (GAAP).

NovoCure Q2 Revenue Jumps 6 Percent

Zacks Investment Research

NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say

The Motley Fool

Novocure: Steady Ahead of Key Milestones

Here's our initial take on Novocure's (NVCR -9.99%) fiscal 2025 second-quarter financial report.

Novocure: Steady Ahead of Key Milestones

Zacks Investment Research

NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates

NovoCure (NVCR) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.31 per share a year ago.

NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates

Novocure Reports Second Quarter 2025 Financial Results

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “With the first half of 2025 complete, I am pleased to report continued progress towards our clinical, regulatory and commercial milestones. In Q2, we gr.

Novocure Reports Second Quarter 2025 Financial Results

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic cancer. These data from PANOVA-3 were accepted as a late-breaking abstract for oral presentation at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2025, taking place July 2 to July 5 in Barcelona, Spain.

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

Zacks Investment Research

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?

See News Rankings

Charts implemented using Lightweight Charts™